Work

Emicizumab Prophylaxis for the Treatment of Infants with Severe Haemophilia A without Factor VIII Inhibitors: Primary Analysis of the HAVEN 7 Study

Year: 2024

Type: conference-paper

Source: Hämostaseologie

DOI: 10.1055/s-0044-1779133

Authors: J. Oldenburg, S. W. Pipe, P. Collins, C. Dhalluin, G. Kenet, C. Schmitt, M. Buri, V. Jiménez-Yuste, F. Peyvandi, G. Young, M. E. Mancuso, K. Kavakli, A. Kiialainen, M. Niggli, T. Chang, M. Lehle, K. Fijnvandraat

Institutions: University Hospital Bonn, University of Michigan, Cardiff University, F. Hoffmann-La Roche AG, Tel Aviv University, Sheba Medical Center, Hospital Universitario La Paz, University of Milan, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Children's Hospital Los Angeles, Humanitas University, IRCCS Humanitas Research Hospital, Ege University, Spark Therapeutics (United States), University of Amsterdam

Language: English

Topic: Hemophilia Treatment and Research

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4392664785

FWCI:

Cites:

Cited by:

Related to: 10